ATE246505T1 - Zubereitung enthaltend cefaclor oder cephalexin mit modifizierter freisetzungsmatrix - Google Patents

Zubereitung enthaltend cefaclor oder cephalexin mit modifizierter freisetzungsmatrix

Info

Publication number
ATE246505T1
ATE246505T1 AT98302445T AT98302445T ATE246505T1 AT E246505 T1 ATE246505 T1 AT E246505T1 AT 98302445 T AT98302445 T AT 98302445T AT 98302445 T AT98302445 T AT 98302445T AT E246505 T1 ATE246505 T1 AT E246505T1
Authority
AT
Austria
Prior art keywords
hydrophilic polymers
cephalexin
active ingredient
weight
cefaclor
Prior art date
Application number
AT98302445T
Other languages
English (en)
Inventor
Jagdish Arora
Girish Jain
Himadri Sen
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Application granted granted Critical
Publication of ATE246505T1 publication Critical patent/ATE246505T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
AT98302445T 1997-12-17 1998-03-30 Zubereitung enthaltend cefaclor oder cephalexin mit modifizierter freisetzungsmatrix ATE246505T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/992,151 US5948440A (en) 1997-12-17 1997-12-17 Modified release matrix formulation of cefaclor and cephalexin

Publications (1)

Publication Number Publication Date
ATE246505T1 true ATE246505T1 (de) 2003-08-15

Family

ID=25537971

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98302445T ATE246505T1 (de) 1997-12-17 1998-03-30 Zubereitung enthaltend cefaclor oder cephalexin mit modifizierter freisetzungsmatrix

Country Status (9)

Country Link
US (1) US5948440A (de)
EP (1) EP0923934B1 (de)
AT (1) ATE246505T1 (de)
AU (1) AU741361B2 (de)
DE (1) DE69816951T2 (de)
DK (1) DK0923934T3 (de)
ES (1) ES2203885T3 (de)
NZ (1) NZ329679A (de)
PT (1) PT923934E (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19845358A1 (de) * 1998-10-02 2000-04-06 Roehm Gmbh Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
IE990406A1 (en) * 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
KR100647901B1 (ko) * 1999-07-09 2006-11-17 보령제약 주식회사 세파클러-함유 서방성 약제조성물 및 그의 제조방법
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
IT1318495B1 (it) * 2000-05-04 2003-08-25 Lisapharma Spa Formulazioni farmaceutiche, a rilascio modificato, con elevatabiodisponibilita', contenenti principi attivi ad attivita'
ATE361060T1 (de) 2000-09-29 2007-05-15 Solvay Pharm Bv Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
ATE319434T1 (de) * 2001-11-19 2006-03-15 Lupin Ltd Pharmazeutische zusammensetzung für die kontrollierte freisetzung eines beta-lactam- antibiotikums
US20040033262A1 (en) * 2002-08-19 2004-02-19 Orchid Health Care Sustained release pharmaceutical composition of a cephalosporin antibiotic
US20040096496A1 (en) * 2002-08-16 2004-05-20 Orchid Chemicals & Pharmaceuticals Limited Sustained release pharmaceutical composition of a cephalosporin antibiotic
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) * 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
WO2005030178A1 (en) * 2003-09-30 2005-04-07 Lupin Ltd. Extended release formulation of beta-lactam antibiotics
WO2005039499A2 (en) * 2003-10-24 2005-05-06 Adhesives Research, Inc. Rapidly disintegrating film
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US8022106B2 (en) 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US20090215898A1 (en) 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
EP1741712B1 (de) * 2004-07-30 2011-06-15 Torrent Pharmaceuticals Ltd amorphes nebivolol hydrochlorid und seine Herstellung
CN101146457B (zh) * 2004-09-30 2012-03-28 好时公司 密封的可食用薄膜条状包装物及其制备和使用方法
ITMI20050391A1 (it) * 2005-03-11 2006-09-12 Ph & T S P A Formulazioni a rilascio controllato di alfuzosin
EP2005946B1 (de) * 2006-04-12 2015-11-18 Nippon Soda Co., Ltd. Herstellungsverfahren einer tablette mit verlängerter freisetzung
PT103884A (pt) * 2006-11-17 2008-05-19 Astrazeneca Ab Composições de libertação prolongada e métodos para a sua preparação
SI2395840T1 (sl) 2009-02-13 2020-08-31 Romark Laboratories, L.C. Farmacevtske formulacije nitazoksanida z nadzorovanim sproščanjem
FR2962550B1 (fr) * 2010-07-06 2013-06-14 Ethypharm Sa Methode pour lutter contre la soumission chimique, utilisation d'agent colorant pour lutter contre la soumission chimique et composition pharmaceutique permettant la mise en oeuvre de la methode
CN101912373B (zh) * 2010-08-24 2012-01-04 北京京丰制药有限公司 稳定的头孢克洛分散片及其制备方法
CN112137984B (zh) * 2020-10-30 2023-02-03 四川制药制剂有限公司 头孢克洛胶囊及其制备工艺
CN113750066B (zh) * 2021-10-12 2022-12-02 上海金城素智药业有限公司 一种具有临床优势的头孢克洛制剂及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US4250166A (en) * 1977-05-27 1981-02-10 Shionogi & Co., Ltd. Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
JPS6024765B2 (ja) * 1981-11-27 1985-06-14 辰巳化学株式会社 セフアレキシンの持続性製剤の製造方法
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4557925A (en) * 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
JPS601128A (ja) * 1983-06-15 1985-01-07 Shionogi & Co Ltd 作用持続型セフアクロル製剤
US4795327A (en) * 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4734285A (en) * 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
DE3607946A1 (de) * 1986-03-11 1987-09-17 Basf Ag Verfahren zur einengung der molekulargewichtsverteilung von polytetrahydrofuran und von copolymerisaten aus tetrahydrofuran und alkylenoxiden
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8616669D0 (en) * 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US4983398A (en) * 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
AU609234B2 (en) * 1987-12-21 1991-04-26 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
ATE216887T1 (de) * 1996-02-29 2002-05-15 Fujisawa Pharmaceutical Co Beta-lactam-antibiotikum enthaltende tabletten und verfahren zu deren herstellung

Also Published As

Publication number Publication date
ES2203885T3 (es) 2004-04-16
EP0923934A1 (de) 1999-06-23
AU741361B2 (en) 2001-11-29
DK0923934T3 (da) 2003-11-24
AU5290698A (en) 1999-07-08
DE69816951D1 (de) 2003-09-11
DE69816951T2 (de) 2004-06-17
PT923934E (pt) 2003-12-31
NZ329679A (en) 1999-10-28
EP0923934B1 (de) 2003-08-06
US5948440A (en) 1999-09-07

Similar Documents

Publication Publication Date Title
DE69816951D1 (de) Zubereitung enthaltend Cefaclor oder Cephalexin mit modifizierter Freisetzungsmatrix
US6177102B1 (en) Once daily analgesic tablet
CN1119993C (zh) 醋氨酚、假麻黄碱、扑尔敏和可有可无的美沙芬的旋转制粒及包衣
CA2592173C (en) Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof
US5133974A (en) Extended release pharmaceutical formulations
KR100283709B1 (ko) 안정한 서방성 경구 투여 조성물
CA1303504C (en) Pharmaceutical formulation containing acrivastine
CA2264238A1 (fr) Forme galenique a liberation prolongee de milnacipran
SI9420040A (en) Extended release, film coated tablet of astemizole and pseudoephedrine
IE53118B1 (en) Substained release pharmaceutical composition
YU71894A (sh) Novi farmaceutski preparat sa difuziono-osmotskom kontrolom oslobađanja leka i postupak za dobivanje istog
IE970588A1 (en) Controlled release pharmaceutical compositions containing tiagabine
DE69909316D1 (de) Pharmazeutische formulierung mit omeprazol
HUT74906A (en) Process for producing medical preparations for treatment of neurologic disorders
NZ322053A (en) Controlled release pharmaceutical formulation comprising an active, a low MW polyethylene oxide, HPMC and one or more enteric polymers
EP0281708A2 (de) Dünnschicht-Zusammensetzung und Anwendung in einem osmotischen System
CZ225596A3 (en) Film-coated tablets of paracetamol and domperidon
CA2000932A1 (en) Oral pharmaceutical controlled release multiple unit dosage form
AU736357B2 (en) Controlled-release pharmaceutical preparation comprising an ACE inhibitor as active ingredient
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
EP0212745B1 (de) Partikel mit konstanter Wirkstofffreisetzung
DE60006362D1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
JP4660192B2 (ja) スフェロイド、その製造方法および医薬組成物
DE1223914T1 (de) Im mund zerfallende zusammensetzung mit mirtazapin
MXPA01008893A (es) Composiciones de betahistina de liberacion controlada.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0923934

Country of ref document: EP

REN Ceased due to non-payment of the annual fee